OncoMed Pharmaceuticals Inc. (OMED)
OncoMed Pharmaceuticals is a clinical-stage biopharmaceutical company. Co. has four anti-cancer therapeutic candidates: Navicixizumab, which is a bispecific monoclonal antibody that targets and inhibits both Delta-like ligand 4, and vascular endothelial growth factor; Anti-TIGIT, which is an inhibitory receptor that stops T-cells from attacking certain tumor cells; GITRL-Fc, which is engineered using a single-gene, linkerless trimer technology that is designed to enable activation of glucocorticoid-induced tumor necrosis factor receptor-related protein; and Rosmantuzumab, which is a monoclonal antibody targeting the RSPO-LGR cancer stem cell pathway.
|
April 19, 2024 6:10 PM Eastern
Hold (2.00 out of 4)
100th percentile
|
|